Conference abstract · 16 Apr 2018
Mini reviewPublished 28 Jul 2022
Natural PPAR Agonist that Doesn't Cause Corpulence
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In clinical settings, PPAR (peroxisome proliferator-activated receptor gamma) agonists are utilized to combat hyperglycemia. The search for new PPAR activators, on the other hand, is fueled by the experience of undesirable side effects like weight gain. We utilized a mix of in silico, in vitro, cell-based and in vivo models to distinguish and approve regular items as promising leads for halfway original PPARγ agonists. It was predicted in silico that the natural product honokiol from the traditional Chinese medicine Magnolia bark would bind as a dimer into the PPAR ligand binding pocket. In fact, in a PPAR-mediated luciferase reporter assay, Honokiol acted as a partial agonist by binding directly to the purified LBD of PPAR. After that, the effects of Honokiol on adipogenic differentiation in 3T3-L1 pre-adipocytes and mouse embryonic fibroblasts and the stimulation of glucose uptake in adipocytes were directly compared to those of the full agonist pioglitazone, which is currently in use in clinical settings. Unlike pioglitazone, which induced adipogenesis, honokiol did not stimulate basal glucose uptake to the same extent as pioglitazone did. The oral administration of honokiol slowed weight gain and prevented hyperglycemia in diabetic KKAy mice. In vivo, we found that honokiol was a partial non-adipogenic PPAR agonist that stopped hyperglycemia and weight gain.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 10 Jun 2019
Novel phenyldiazenyl fibrate analogues as PPAR agonists: Design, synthesis and pharmacological evaluation
Article · 3 May 2019
Three Dimensional Quantitative StructuralÃ?¢Ã?â?¬Ã?â??Activity Relationship (3D-QSAR) Studies some 3-{4-[3-(2-aryl-phenoxy) butoxy]-phenyl} Propionic acids as novel PPAR Ã?ŽÃ?³/Ã?ŽÃ?´ agonists
Conference abstract · 14 Jun 2018
Design synthesis and biological evaluation of fibrate analogues as PPAR agonists
Conference abstract · 29 May 2017
Encapsulation of agonist PPAR- γ in polymeric nanoparticles to treat ocular inflammatory processes
More from this journal
The newest in Journal of Pharmacognosy & Natural Products.
Article · 19 Feb 2026
Determination of Some Sulphonyl Chlorides Using Titrimetric and Polarographic Procedures
Brief report · 29 Dec 2025
Saponins: Broad Therapeutic Potential and Applications
Brief report · 29 Dec 2025
Flavonoids: Diverse Benefits, Broad Health Impact
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacognosy & Natural Products
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Javier Gal”

